Examples of using Thymanax in English and their translations into Slovak
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
The CHMP noted that Thymanax's benefits in terms of treating depression might be lower than seen with other antidepressants.
In addition, the company that makes Thymanax will supply educational material for doctors prescribing Thymanax.
The efficacy and safety of Thymanax in major depressive episodes have been studied in a clinical programme including 5,800 patients of whom 3,900 were treated with Thymanax.
The incidence of relapse during the 6-months double-blind follow up period was 22% and 47% for Thymanax and placebo, respectively.
while you are taking Thymanax.
the CHMP was of the opinion that the benefits of Valdoxan/ Thymanax did not outweigh its risks.
What are the consequences of the refusal for patients undergoing clinical trials/ compassionate use programmes with Valdoxan/ Thymanax?
compassionate use programmes with Valdoxan/ Thymanax.
The company also presented the results of a further study comparing Thymanax with sertraline(another antidepressant).
If your doctor changes your previous antidepressant medicine from an SSRI or SNRI to Thymanax, he/she will advise you on how you should discontinue your previous medicine when starting Thymanax.
Thymanax 25- 50 mg once daily demonstrated a statistically significant superiority compared to placebo(p=0.0001)
You should not take Thymanax together with certain medicines(see also under“ Do not take Thymanax” in section 2): fluvoxamine(another medicine used in the treatment of depression), ciprofloxacin(an antibiotic).
after launch all physicians who are expected to prescribe or use Thymanax are provided with the updated educational material containing the following.
you should receive or continue using Thymanax(see also under“How to take Valdoxan” in section 3).
If you take more Thymanax than you should If you have taken more Thymanax than you should, or if for example a child has taken medicine by accident, contact your doctor immediately.
The European Medicines Agency has deferred the obligation to submit the results of studies with Thymanax in one or more subsets of the paediatric population in the treatment of major depressive episodes(see section 4.2 for information on paediatric use).
The experience of overdoses with Thymanax is limited
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Thymanax therapy taking into account the benefit of breast feeding for the child
A patient booklet will also be distributed to all patients who are prescribed Thymanax so that they are aware of the risk to the liver,
pharmacodynamic interaction with medicinal products which could be prescribed concomitantly with Thymanax in the target population was found in phase I clinical trials: